Lantern Pharma Inc. (LTRN) shareholders
Close on Nov 17, 2026Market cap $4.67MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ryan M. Lane Joint filing with Empery Asset Management, LP (9.99%) | 1,322,551 | 9.99% | 13G (passive) | Jun 30, 2026 |
| Leslie W. Kreis Joint filing with Cavu Management, LP (9.98%), Bios Capital Management, LP (9.98%) and 3 more | 1,075,952 | 9.98% | 13D (active) amendment | Jun 12, 2025 |
| Thomas A. Satterfield, Jr. | 975,000 | 7.60% | 13G (passive) amendment | Jun 30, 2026 |
| Cavu Advisors, LLC Joint filing with Bios Capital Management, LP (8.58%), Bios Advisors Gp, LLC (8.58%) and 3 more | 960,026 | 8.58% | 13D (active) amendment | Feb 20, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LTRN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 842,669 | 6.59% | $3.51M | New | 4.06% |
| CM Management, LLC | 500,000 | 3.91% | $2.09M | +250,000 | 1.39% |
| Vanguard Capital Management LLC | 425,118 | 3.33% | $1.77M | +93,039 | 0.00% |
| Renaissance Technologies LLC | 291,039 | 2.28% | $1.21M | +175,039 | 0.00% |
| BIOS Capital Management, LP | 249,397 | 1.95% | $1.04M | −615,038 | 2.50% |
| Geode Capital Management, LLC | 102,819 | 0.80% | $428.85K | −8,827 | 0.00% |
| Vanguard Fiduciary Trust Co | 49,950 | 0.39% | $208.29K | +343 | 0.00% |
| Citadel Advisors LLC | 47,895 | 0.37% | $199.72K | New | 0.00% |
| Westside Investment Management, Inc. | 47,850 | 0.37% | $199.54K | −2,200 | 0.03% |
| Quadrature Capital Ltd | 39,593 | 0.31% | $165.10K | New | 0.00% |
| NewEdge Advisors, LLC | 27,049 | 0.21% | $112.80K | −350 | 0.00% |
| Horizon Kinetics Asset Management LLC | 25,164 | 0.20% | $104.93K | −1,209 | 0.00% |
| DAVENPORT & Co LLC | 23,814 | 0.19% | $99.30K | – | 0.00% |
| State Street Corp | 23,652 | 0.19% | $98.63K | – | 0.00% |
| BlackRock, Inc. | 22,350 | 0.17% | $93.20K | −22,917 | 0.00% |
| Bank of New York Mellon Corp | 21,301 | 0.17% | $88.83K | – | 0.00% |
| Northern Trust Corp | 17,485 | 0.14% | $72.91K | +1,896 | 0.00% |
| XTX Topco Ltd | 17,415 | 0.14% | $72.62K | New | 0.00% |
| Dimensional Fund Advisors LP | 16,725 | 0.13% | $69.74K | −21,335 | 0.00% |
| UBS Group AG | 16,632 | 0.13% | $69.36K | +6,555 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 39 | 3M | 22.6% | 12 / 9 | 8 / 6 | 2M | 1M |
| Q1 2026 | 33 | 2M | 16.4% | 5 / 9 | 9 / 3 | 0M | 0M |
| Q4 2025 | 33 | 2M | 17.8% | 6 / 6 | 9 / 4 | 0M | 0M |
| Q3 2025 | 31 | 2M | 17.9% | 3 / 9 | 8 / 7 | 0M | 0M |
| Q2 2025 | 35 | 2M | 17.6% | 8 / 11 | 5 / 5 | 0M | 0M |
| Q1 2025 | 32 | 2M | 19.0% | 3 / 10 | 5 / 3 | 0M | 0M |
| Q4 2024 | 32 | 2M | 19.6% | 6 / 8 | 10 / 5 | 1M | 0M |
| Q3 2024 | 31 | 1M | 10.4% | 4 / 9 | 8 / 11 | 0M | 0M |
| Q2 2024 | 39 | 1M | 10.1% | 11 / 8 | 12 / 6 | 0M | 0M |
| Q1 2024 | 34 | 1M | 8.7% | 10 / 9 | 10 / 6 | 0M | 0M |
| Q4 2023 | 30 | 1M | 9.0% | 3 / 6 | 13 / 0 | 0M | 0M |
| Q3 2023 | 27 | 1M | 9.0% | 3 / 5 | 8 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
13 funds held LTRN in Q2 2026, 81% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LTRN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 338,385 | 2.65% | $1.41M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 81,101 | 0.63% | $338.19K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 47,619 | 0.37% | $170.95K | 0.00% | May 31, 2026 |
| Horizon Kinetics Medical ETF | 25,164 | 0.20% | $104.93K | 0.55% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 15,273 | 0.12% | $54.83K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 11,259 | 0.09% | $40.42K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 6,838 | 0.05% | $24.55K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 4,832 | 0.04% | $20.15K | 0.00% | Jun 30, 2026 |
| Dimensional US Sustainability Core 1 ETF | 1,924 | 0.02% | $5.06K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 643 | 0.01% | $1.69K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Panna Sharma | President & CEO, Director | – | – | Sep 23, 2025 |
| Kishor G. Bhatia | Chief Scientific Officer | – | – | Dec 22, 2025 |
| David R. Margrave | Chief Financial Officer | – | – | Dec 22, 2025 |
| Lee Troy Schalop | Director | 48,544 | 0.38% | May 14, 2026 |
| D. Jeffrey Keyser | Director | 94,303 | 0.74% | May 14, 2026 |
| David S. Silberstein | Director | 1,044,000 | 8.17% | Jan 13, 2026 |
| Vijay Chandru | Director | – | – | Jan 13, 2026 |
| Maria-Luisa Maccecchini | Director | – | – | Jan 13, 2026 |
| BIOS Fund II, LP | 10% owner | 1,883,025 | 14.73% | Jun 13, 2025 |
| BIOS Fund I QP, LP | 10% owner | – | – | Jun 13, 2025 |
| Aaron G.L. Fletcher | 10% owner | 1,233,802 | 9.65% | Jun 13, 2025 |
| BIOS Advisors GP, LLC | 10% owner | 1,177,565 | 9.21% | Jun 13, 2025 |
| BIOS Fund II QP, LP | 10% owner | 1,075,952 | 8.42% | Jun 13, 2025 |
| BIOS Fund II NT, LP | 10% owner | – | – | Jun 13, 2025 |
| Bios Equity Partners, LP | 10% owner | 304,498 | 2.38% | Jun 13, 2025 |
| Leslie W. Kreis | 10% owner | 1,761,146 | 13.78% | Jun 13, 2025 |
| Cavu Management, LP | 10% owner | 1,387,670 | 10.85% | Jun 13, 2025 |
| Cavu Advisors, LLC | 10% owner | 1,115,952 | 8.73% | Jun 13, 2025 |
| BP Directors, LP | 10% owner | 1,075,952 | 8.42% | Jun 13, 2025 |
| BIOS Fund I, LP | 10% owner | 1,115,952 | 8.73% | Jun 13, 2025 |
| Bios Equity Partners II, LP | 10% owner | 1,263,802 | 9.89% | Jun 13, 2025 |
| BIOS Capital Management, LP | 10% owner | – | – | Jun 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| D. Jeffrey Keyser Director | May 12, 2026 | Buy | +48,544 | $2.06 | $100.00K | 94,303 |
| Lee Troy Schalop Director | May 12, 2026 | Buy | +48,544 | $2.06 | $100.00K | 48,544 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −7,206 | $3.09 | $22.27K | 189,117 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −1,903 | $3.09 | $5.88K | 49,957 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −4,354 | $3.09 | $13.45K | 114,272 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −12,319 | $3.09 | $38.07K | 323,335 |
| BP Directors, LP 10% owner | Jun 13, 2025 | Sale | −14,218 | $3.09 | $43.93K | 373,178 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −7,206 | $3.09 | $22.27K | 189,117 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −14,218 | $3.09 | $43.93K | 373,178 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −1,903 | $3.09 | $5.88K | 49,957 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −4,354 | $3.09 | $13.45K | 114,272 |
| BIOS Fund II QP, LP 10% owner | Jun 13, 2025 | Sale | −12,319 | $3.09 | $38.07K | 323,335 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −18,678 | $3.38 | $63.13K | 335,654 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −2,886 | $3.38 | $9.75K | 51,860 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −21,557 | $3.38 | $72.86K | 387,396 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −6,601 | $3.38 | $22.31K | 118,626 |
| BIOS Fund I, LP 10% owner | Jun 12, 2025 | Sale | −10,925 | $3.38 | $36.93K | 196,323 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −2,886 | $3.38 | $9.75K | 51,860 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −21,557 | $3.38 | $72.86K | 387,396 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −6,601 | $3.38 | $22.31K | 118,626 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −18,678 | $3.38 | $63.13K | 335,654 |
| Cavu Advisors, LLC 10% owner | Jun 12, 2025 | Sale | −10,925 | $3.38 | $36.93K | 196,323 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −293 | $3.40 | $996 | 354,332 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −45 | $3.40 | $153 | 54,746 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −338 | $3.40 | $1.15K | 408,953 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −103 | $3.40 | $350 | 125,227 |
| BIOS Fund I, LP 10% owner | Jun 11, 2025 | Sale | −171 | $3.40 | $581 | 207,248 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −338 | $3.40 | $1.15K | 408,953 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −103 | $3.40 | $350 | 125,227 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −293 | $3.40 | $996 | 354,332 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −171 | $3.40 | $581 | 207,248 |
| Cavu Advisors, LLC 10% owner | Jun 11, 2025 | Sale | −45 | $3.40 | $153 | 54,746 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −5 | $3.40 | $17 | 409,291 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −2 | $3.40 | $7 | 125,330 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −3 | $3.40 | $10 | 207,419 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −5 | $3.40 | $17 | 354,625 |
| BIOS Fund I, LP 10% owner | Jun 10, 2025 | Sale | −1 | $3.40 | $3 | 54,791 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −5 | $3.40 | $17 | 409,291 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −2 | $3.40 | $7 | 125,330 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −1 | $3.40 | $3 | 54,791 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −5 | $3.40 | $17 | 354,625 |
| Cavu Advisors, LLC 10% owner | Jun 10, 2025 | Sale | −3 | $3.40 | $10 | 207,419 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −3,639 | $3.03 | $11.03K | 207,422 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −6,221 | $3.03 | $18.85K | 354,630 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −961 | $3.03 | $2.91K | 54,792 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −7,180 | $3.03 | $21.76K | 409,296 |
| BIOS Advisors GP, LLC 10% owner | May 29, 2025 | Sale | −2,199 | $3.03 | $6.66K | 125,332 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −961 | $3.03 | $2.91K | 54,792 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −7,180 | $3.03 | $21.76K | 409,296 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −6,221 | $3.03 | $18.85K | 354,630 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −3,639 | $3.03 | $11.03K | 207,422 |
| Cavu Advisors, LLC 10% owner | May 29, 2025 | Sale | −2,199 | $3.03 | $6.66K | 125,332 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −1,632 | $2.87 | $4.68K | 127,531 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −2,702 | $2.87 | $7.75K | 211,061 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −4,620 | $2.87 | $13.26K | 360,851 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −714 | $2.87 | $2.05K | 55,753 |
| BIOS Advisors GP, LLC 10% owner | May 28, 2025 | Sale | −5,332 | $2.87 | $15.30K | 416,476 |
| Cavu Advisors, LLC 10% owner | May 28, 2025 | Sale | −714 | $2.87 | $2.05K | 55,753 |
| Cavu Advisors, LLC 10% owner | May 28, 2025 | Sale | −5,332 | $2.87 | $15.30K | 416,476 |
| Cavu Advisors, LLC 10% owner | May 28, 2025 | Sale | −1,632 | $2.87 | $4.68K | 127,531 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lantern Pharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 16,546 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| BIOS Fund II NT, LP Affiliate (10% owner) | May 27, 2025 | 25,849 | $85.03K | May 27, 2025 | Conversion of Shares in IPO |
| BIOS Fund I QP, LP Affiliate (10% owner) | May 27, 2025 | 29,576 | $97.31K | May 27, 2025 | Conversion of Shares in IPO |
| BIOS Fund II, LP Affiliate (10% owner) | May 27, 2025 | 53,454 | $175.86K | May 27, 2025 | Conversion of Shares in IPO |
| BIOS Fund I, LP Affiliate (10% owner) | May 27, 2025 | 75,941 | $249.85K | May 27, 2025 | Conversion of Shares in IPO |
| BIOS Fund II QP, LP Affiliate (10% owner) | May 27, 2025 | 105,180 | $346.04K | May 27, 2025 | Conversion of Shares in IPO |
| BIOS Fund I, LP Affiliate (10% owner) | Apr 26, 2024 | 371,950 | $1.99M | Apr 29, 2024 | Conversion of Shares in IPO |
| BIOS Fund II NT, LP Affiliate (10% owner) | Apr 26, 2024 | 54,597 | $291.55K | Apr 29, 2024 | Conversion of Shares in IPO |
| BIOS Fund II, LP Affiliate (10% owner) | Apr 26, 2024 | 124,887 | $666.90K | Apr 29, 2024 | Conversion of Shares in IPO |
| BIOS Fund II QP, LP Affiliate (10% owner) | Apr 26, 2024 | 407,845 | $2.18M | Apr 29, 2024 | Conversion of Shares in IPO |
| BIOS Fund I QP, LP Affiliate (10% owner) | Apr 26, 2024 | 217,553 | $1.16M | Apr 29, 2024 | Conversion of Shares in IPO |
| BIOS Fund II, LP Affiliate (10% owner) | Feb 28, 2024 | 30,650 | $119.84K | Feb 27, 2024 | Conversion of Shares in IPO |
| BIOS Fund II NT, LP Affiliate (10% owner) | Feb 28, 2024 | 13,417 | $52.46K | Feb 27, 2024 | Conversion of Shares in IPO |
| BIOS Fund II QP, LP Affiliate (10% owner) | Feb 28, 2024 | 100,236 | $391.92K | Feb 27, 2024 | Conversion of Shares in IPO |
See a number that looks wrong?